CBD/Cannabidiol has shown to reduce anxiety and a host of other disorders. The primary noneuphorizing and nonaddictive compound of cannabis, cannabidiol (CBD), has shown to possess considerable therapeutic potential for treating a wide range of neuropsychiatric disorders. They include chronic pain, nausea, epilepsy, psychosis and anxiety. CBD in therapeutics is used within a large therapeutic window, which ranges from 2.85 to 50 mg/kg/day.
Social anxiety disorder (SAD) was the basis of the research from which this article is taken. SAD is characterized by excessive anxiety in situations where a person might feel judged, such as performance situations, and situations involving interpersonal contact with others (American Psychiatric Association, 2000). This is the fear of social situations that may cause humiliation or embarrassment. While it is one of the common anxiety disorders. Prevalence rates reported in the literature vary across studies. For instance, lifetime prevalence estimates for SAD based on large community samples in the United States range from 3 to 13%. In addition, some studies report that SAD has a higher incidence in females than in males.
Developmentally, SAD is likely to not only begin in adolescence (mid to late teens) but can also occur earlier in childhood. A significant number of adult’s report that they have had problems with social anxiety for their entire lives or as long as they can remember. A large-scale study of individuals presenting at an anxiety clinic found a mean age of onset of 15.7 years, a number that was younger than the onset of other anxiety disorders.
SAD in the past has been best treated with psychotropic medication and cognitive behavioral therapies (CBT), and the most effective treatments have been a combination of both. They consist of monoamine oxidase inhibitors, the serotonin reuptake inhibitors, benzodiazepines, and individual cognitive behavioral therapy. CBT typically includes 10–15 weekly sessions and consists of a variety of strategies, such as self-monitoring, psychoeducation, cognitive therapy, exposure-based techniques, and social skills training. While this method has been proven to be effective for SAD if it is executed, it is also true that people with the disorder quite often show unwillingness to receive CBT. In fact, a study reported that 92% of individuals with SAD expressed concerns about starting treatment and that is the biggest barrier to treatment that should be overcome.
In this regard, preliminary findings reported by a study that investigated the efficacy of CBD with patients with SAD are noteworthy. In that study patients with SAD were provided with a single dose of CBD (600 mg). When the anxiety induced the difference between pretreatment and posttreatment, its level showed a significant decrease after the treatment, whereas no such change was observed in the placebo group of patients.
The purpose of the current study was to pursue this issue further and to investigate the possible efficacy of CBD as at least an adjunctive option for intervention in people with SAD. While SAD has been classified into several subtypes so far, the author concentrated the research on that with avoidant personality disorder because this subtype is the most commonly diagnosed and is becoming a serious social problem in Japan, where the current study was conducted.